 | Up a level |
Manns, Michael; Samuel, Didier; Gane, Edward J; Mutimer, David; McCaughan, Geoff; Buti, Maria; Prieto, Martín; Calleja, José Luis; Peck-Radosavljevic, Markus; Müllhaupt, Beat; Agarwal, Kosh; Angus, Peter; Yoshida, Eric M; Colombo, Massimo; Rizzetto, Mario; Dvory-Sobol, Hadas; Denning, Jill; Arterburn, Sarah; Pang, Phillip S; Brainard, Diana; ... (2016). Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet infectious diseases, 16(6), pp. 685-697. Elsevier 10.1016/S1473-3099(16)00052-9
Rauch, Andri; James, Ian; Pfafferott, Katja; Nolan, David; Klenerman, Paul; Cheng, Wendy; Mollison, Lindsay; McCaughan, Geoff; Shackel, Nick; Jeffrey, Gary P; Baker, Ross; Freitas, Elizabeth; Humphreys, Isla; Furrer, Hansjakob; Günthard, Huldrych F; Hirschel, Bernard; Mallal, Simon; John, Mina; Lucas, Michaela; Barnes, Eleanor; ... (2009). Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 50(4), pp. 1017-29. Hoboken, N.J.: Wiley Interscience 10.1002/hep.23101
Gaudieri, Silvana; Rauch, Andri; Pfafferott, Katja; Barnes, Eleanor; Cheng, Wendy; McCaughan, Geoff; Shackel, Nick; Jeffrey, Gary P; Mollison, Lindsay; Baker, Ross; Furrer, Hansjakob; Günthard, Huldrych F; Freitas, Elizabeth; Humphreys, Isla; Klenerman, Paul; Mallal, Simon; James, Ian; Roberts, Stuart; Nolan, David and Lucas, Michaela (2009). Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology, 49(4), pp. 1069-82. Hoboken, N.J.: Wiley Interscience 10.1002/hep.22773
